Antivirals

SUMMARY

This report analyzes the worldwide markets for Antivirals in US$ Million. The major product segments analyzed are HIV Antivirals (Reverse Transcriptase Inhibitors (RTIs) (Nucleotide Reverse Transcriptase Inhibitors (NRTIs), and Non-Nucleotide Reverse Transcriptase Inhibitors (NNRTIs)), and Protease Inhibitors (PIs), Hepatitis B & C Antivirals (Hepatitis C Antivirals, and Hepatitis B Antivirals), Herpes Simplex Virus (HSV) Antivirals, Influenza Antivirals, Respiratory Syncytial Virus (RSV) Antivirals, and Human Papilloma Virus (HPV) Antivirals. The report provides separate comprehensive analytics for the US, Japan, Europe and Rest of World. Annual forecasts are provided for the period of 2000 through 2010. The report profiles 139 companies including many key and niche players worldwide such as Abbott Laboratories, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline Plc., Hoffmann-La Roche, Merck & Co., Novartis AG, Pfizer Inc., Schering-Plough Corp. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

TABLE OF CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

• Study Reliability and Reporting Limitations I-1
• Disclaimers I-2
• Data Interpretation & Reporting Level I-2
• Quantitative Techniques & Analytics I-2
• Product Definitions and Scope of Study I-3
• HIV Antivirals I-3
• NRTIs I-4
• NNRTIs I-4
• Protease Inhibitor (PI) I-4
• Other HIV Antivirals I-4
• Hepatitis B & C Antivirals I-4
• Hepatitis B Antivirals I-5
• Hepatitis C Antivirals I-5
• Herpes Simplex Virus (HSV) Antivirals I-5
• Influenza Antivirals I-5
• Respiratory Syncytial Virus (RSV) Antivirals I-6
• Human Papilloma Virus (HPV) Antivirals I-6
• Other Antivirals I-6

II. EXECUTIVE SUMMARY

1. Market Overview II-1

• Viruses, a Difficult - to - Treat Class of Parasites II-1
• United States - The Largest Market for Antivirals Globally II-1
• Five Major Antivirals Dominate the Overall Antivirals Arena II-2
• Table 1: Worldwide Infectious Disease Drugs Market by Class: 2005 Percentage Share Breakdown by Typefor Antivirals, Quinolones, Macrolides, Penicillins, Cephalosporins, Antifungals, Tetracyclines, Erythromycins and Other Therapies in US$ million (includes corresponding Graph/Chart) II-2
• Anti-HIV Drugs - The Largest Antivirals Category Worldwide II-2
• US - Largest Region, and Japan - Fastest Growing Region for HIV Antivirals II-3
• Table 2: World HIV Antivirals Market by Geographic Region - US, Japan, Europe and Rest of World (excluding Japan) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 & 2010 (includes corresponding Graph/Chart) II-3
• Table 3: World HIV Antivirals Market by Geographic Region - Percentage Share Breakdown for US, Japan, Europe, and Rest of World (excluding Japan) for the Year 2006 (includes corresponding Graph/Chart) II-3
• Leading Players and Drugs II-4
• Top 10 HIV Antiviral Drug Candidates by Global Sales II-4
• New Drugs in Pipeline to Boost up the HIV
• Antivirals Sales II-4
• Hepatitis Antivirals - A Significant Market II-4
• US Dominates the Hepatitis B & C Antivirals Market II-5
• Table 4: World Hepatitis B & C Antivirals Market by Geographic Region - US, Japan, Europe and Rest of World (excluding Japan) with Annual Sales Figures in US$ Million for Years 2006 & 2010 (includes corresponding Graph/Chart) II-5
• Hepatitis C Antivirals - The Fastest Growing Antivirals Segment II-5
• U S Dominates the Hepatitis C Antivirals Market II-6
• Table 5: World Hepatitis C Antivirals Market by Geographic Region - US, Japan, Europe and Rest of World (excluding Japan) with Annual Sales Figures in US$ Million for Years 2006 & 2010 (includes corresponding Graph/Chart) II-6
• The US Dominates the Hepatitis B Antivirals Market II-6
• Table 6: World Hepatitis B Antivirals Market by Geographic Region - US, Japan, Europe and Rest of World (excluding Japan) with Annual Sales Figures in US$ Million for Years 2006 & 2010 (includes corresponding Graph/Chart) II-7
• Growing Patient Population to Drive up Hepatitis B Drugs Market II-7
• Influenza Anti-Virals II-7
• Rising Threat of Avian Flu to Drive up the Market for Antivirals II-7
• Herpes and Respiratory Antivirals II-8
• HSV/VZV Drugs Dominate the Herpes and Respiratory Antivirals Market II-8
• Launch of New Drugs to Drive up the Market for Respiratory Antivirals II-8

2. Competitive Landscape II-9

• Players Active in the HIV Antivirals Market II-10
• Table 7: Leading Drug Brands for HIV Infection in the World: 2005 Sales (in $ million) for Combivir, Kaletra, Viread, Reyataz, Sustiva, Trizivir, Epivir, and Epzicom/Kivexa (includes corresponding Graph/Chart) II-10
• Major HIV Antivirals Brands Available in the Market II-10
• Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Brands - II-10
• Epivir (Lamivudine) II-10
• Retrovir (Zidovudine) II-10
• Combivir (Epivir+Retrovir) II-11
• Videx (Didanosine) II-11
• Zerit (Stavudine) II-11
• Hivid (Zalcitabine) II-11
• Protease Inhibitors (PIs) - II-11
• Norvir (Ritonavir) II-11
• Kaletra (Lopinavir+Ritonavir) II-11
• Agenerase (Amprenavir) II-11
• (VX-175) Fosamprenavir II-12
• VX-385 II-12
• Fusion Inhibitors - II-12
• Fuzeon (Enfuvirtide) II-12
• Players Active in the Hepatitis B Virus (HBV) Drugs Market II-12
• Hepsera Leads the Oral Hepatitis B Antivirals Market II-12
• Table 8: Leading Drug Brands for Oral Hepatitis B Antivirals: 2006 Percentage Share Breakdown for Hepsera, Epivir HBV and Baraclude (includes corresponding Graph/Chart) II-12
• Table 9: Leading Antivirals Brands for Hepatitis B Infection in the World: 2005 Sales (in $million) for *Engerix-B, Havrix, and Twinrix; **Infanrix and Pediarix, and Epivir (includes corresponding Graph/Chart) II-13
• Players in the Hepatitis C Virus (HCV) Drugs Market II-13
• Table 10: Leading Drug Brands for Oral Hepatitis B Antivirals in the World: 2005 Sales (in $million) for Pegasys and PEG-Intron II-13
• Table 11: Leading Players in the Pegylated Interferons Market in the World: 2006 Percentage Share Breakdown by Player for Hoffmann-La Roche, Schering-Plough and Others (includes corresponding Graph/Chart) II-14
• Table 12: Leading Therapies for Hepatitis C Infection in the World: 2006, 2010E and 2015E Percentage Share Breakdown for Ribavirin, Interferons, Protease Inhibitors, and Nucleoside Analogs (includes corresponding Graph/Chart) II-14
• Players in the Herpes and Respiratory Antiviral Market II-15
• Table 13: Leading Brands of the Respiratory Antivirals Market in the World: 2005 Sales (in $million) for Tamiflu; Synagis; Infanrix and Pediarix (includes corresponding Graph/Chart) II-15
• Players in the Herpes Simplex Virus (HSV) Therapies Market II-15
• Table 14: Leading Drug Brands for Oral Herpes Antivirals in the World: 2004 Sales (in $million) for Valtrex and Zovirax II-16
• Major HSV Infection Drugs Available II-16
• Zovirax (Aciclovir) II-16
• Famvir (Famciclovir) II-16
• Foscavir (Foscarnet) II-16
• Valtrex (Valaciclovir) II-16
• Vectavir/Denavir (Penciclovir) II-17
• Abreva (Docosanol) II-17
• Players in the Influenza Market II-17
• Major Influenza Drugs Available II-17
• Symmetrel® (Amantadine) II-17
• Flumadine (Rimantadine) II-17
• Tamiflu (Oseltamivir) II-17
• Relenza (Zanamivir) II-18
• Players in the Antivirals (Non-HIV) Market II-18
• Table 15: Global Leading Players in the Antivirals (Non-HIV) Market: 2005 Percentage Share Breakdown for GlaxoSmithKline (GSK), Novartis, Roche, Schering-Plough and Others (includes corresponding Graph/Chart) II-18
• Players Active in the Antiviral Vaccines Market II-18
• Table 16: Leading Antiviral Vaccines Sales (in US$ million) in US/Europe in 2003 (includes corresponding Graph/Chart) II-19
• Table 17: Leading Players in the US & **5EU Vaccines Markets: 2005 Percentage Share Breakdown by Player for GlaxoSmithKline (GSK), Sanofi-Aventis, Merck, *Novartis (Chiron) and Others (includes corresponding Graph/Chart) II-19
• Product Pipeline Development of Hepatitis C Drugs as of 2006 II-20

3. Market Trends & Issues II-21

• Increased Investment in R&D to Fuel Growth II-21
• Preventative Antivirals Gains Significance II-21
• New Drug Types Fuels Up the HIV Drugs Sector II-21
• Development of Direct Targeted Antiviral Therapies II-22
• Advent of Novel Anti-Viral Peptides II-22
• siRNA Shows Potential to Function as Antiviral Agent II-23
• Reduction of HIV/AIDS Therapy Costs Boost Market Growth II-23
• Combination Drug Therapy Gains Popularity in the Anti-HIV Drugs Market II-23
• Empowering Women to Fight Against Spread of HIV Infection II-23
• Prices to Go Up for Novel Antivirals II-24
• Competition Scales up for Nucleoside/Nucleotide Analogs Class of Hepatitis Antivirals II-24
• Emergence of Oligonucleotide (ODN) Agents in HIV Drugs Market II-24
• PMBs to Invade the Antivirals Market II-24
• Acute Shortage Witnessed for the Influenza Vaccine for the 2004-05 Season II-24
• New Therapies for Treatment Naïve Hepatitis Patients II-25
• Adult and Travel Vaccines to Drive Up the Market for Antiviral Vaccines II-25
• Researches to Develop Antivirals for Other Miscellaneous Viral Diseases on Full Swing II-25
• Growth to Slow Down Considerably for Herpes Antiviral Market II-25
• STDs, a Major Concern the World Over II-25
• Microbiocides, a New Way to Fight STD and HIV Infections II-26
• Spread of HIV Infection Poses a Global Health Risk II-26

4. An Overview of Major Viral Epidemics &

• Pandemics in the World II-28
• HIV/AIDS Pandemics II-28
• HIV/AIDS Cases for 2005 in the World II-28
• Highlights of AIDS Epidemic II-28
• Table 18: Global HIV/AIDS Statistics in 2005
• (in Million) (includes corresponding Graph/Chart) II-29
• Table 19: Regional Statistics for HIV/AIDS Cases in 2005 (in Million) (includes corresponding Graph/Chart) II-30
• Table 20: Deaths Due to AIDS Worldwide: Breakdown by Region- 2004 (in Million) (includes corresponding Graph/Chart) II-30
• Table 21: HIV/AIDS Cases in Adults and Children Worldwide: Breakdown by Region-End 2004 II-31
• Table 22: Countries With the Highest Number of People Living with HIV: 2003 (includes corresponding Graph/Chart) II-31
• Various Organizations Actively Supports HIV/AIDS Awareness and Preventive Measures Programs II-32
• Table 23: Regional Distribution of Requirement of Funding for Prevention of AIDS: Percentage Share Breakdown for Africa, East Asia-Pacific, South & South East Asia, Eastern Europe, Latin America & Caribbean Region, and North Africa & Middle East in 2006 (includes corresponding Graph/Chart) II-32
• Table 24: Regional Distribution of Requirement of Funding for Treatment and Care of AIDS: Percentage Share Breakdown for Africa, Latin America & Caribbean Region, East Asia-Pacific, Eastern Europe, South & South East Asia, and North Africa & Middle East in 2006 (includes corresponding Graph/Chart) II-32
• Hepatitis B Virus (HBV) Infection Epidemic II-32
• Hepatitis C Virus (HCV) Infection Epidemic II-33
• Table 25: Diagnosis of Hepatitis C Infection in the World: 2005 Percentage Share Breakdown by Transmission Category for Injecting Drug Use (IDU), Sexual Contact, Contaminated Blood Transfusion and Others (includes corresponding Graph/Chart) II-33
• Influenza - Major Outbreaks II-34

5. Anti-Virals : Product Overview II-35

• What are Viruses? II-35
• RNA & DNA Viruses II-35
• Emergence of Antivirals II-35
• Functions of Antivirals II-36
• Design Strategies for Antivirals Drugs II-36
• Vaccines, the Antivirals for Initial Stage of Viral Infection II-36
• Antivirals for Other Stages of Viral Life Cycle II-36
• Entry Blockers II-36
• Viral Component Replication Blockers II-37
• Viral Component Assimilation Blockers II-37
• Antisense Molecules II-37
• Synthetic Ribozymes II-37
• Protease Inhibitors II-38
• Blockers for Release of Completed Viruses from the Host Cell II-38
• Other Types of Antivirals II-38
• Interferons II-38
• Synthetic Monoclonal Antibodies II-38
• Factors Governing Developments in Antiviral Technology II-38

6. Major Viral Infections and Treatment Worldwide II-39

• Human Immunodeficiency Virus (HIV) II-39
• Transmission of HIV Infection II-39
• Infection Process - Targets for HIV Therapy II-40
• Symptoms of the Infection II-40
• Most Vulnerable Demographics for HIV Infection II-41
• Preventive Methods for Controlling HIV Infection II-42
• Methods for the Measurement of Viral Load in Patients II-42
• Methods for Determining Drug Resistance in HIV Positive Patients II-42
• Major HIV/AIDS Testing Methods Available II-43
• Diagnostic Tests II-43
• I. Antibody Tests II-43
• A. HIV-1 Screening Tests II-43
• a. Enzyme-linked Immunosorbent Assays/Enzyme Immunoassays (ELISA/EIA) II-43
• b. Home AccessHIV-1 test system/Dried Blood Spot II-44
• c. Rapid Tests... II-44
• B. HIV-1 Antibody Confirmatory Tests II-44
• a. The Western Blot Test II-44
• b. Indirect Immunofluorescent Antibody Assay (IFA) II-44
• c. Line Immunoassay II-45
• d. Radioimmunoprecipitation Assay (RIPA) II-45
• C. HIV-2 Diagnostic Tests and HIV Group "O II-45
• Major Trends in the HIV/AIDS Testing Market II-45
• Rapid Testing- Displays High Potential II-45
• FDA Approved Rapid HIV Tests in US II-46
• Molecular Diagnostics Register Strong Growth in Blood Screening Markets II-46
• Ultra-Rapid HIV-screening tests- A Strong Fight against HIV-Epidemic II-46
• Emergency Room Testing to Help HIV Diagnosis II-46
• Treatments Available for HIV/AIDS Infections II-46
• Major HIV/AIDS Drug Categories Available II-47
• NRTIs II-47
• NNRTIs II-47
• GW695634 II-47
• Protease Inhibitor (PI) II-48
• (VX-175) Fosamprenavir II-48
• VX-385 II-48
• Integrase Inhibitors (IIs) II-48
• S-1360 II-48
• Entry Blockers II-48
• Fusion Inhibitors II-49
• Fuzeon (Enfuvirtide) II-49
• Antiviral siRNAs II-49
• New Products in Pipeline II-49
• HIV Vaccines II-49
• Hepatitis Infection II-50
• Acute Hepatitis Infection II-50
• Chronic Hepatitis Infection II-50
• Treatment Regimens for Hepatitis Infection II-50
• Interferons II-50
• Standard Interferons II-51
• Pegylated Interferons II-51
• Pegasys II-51
• N & PEG-Intron Redipen II-51
• Pegasys Pack II-51
• N & Pegatron II-51
• Ribavirin II-51
• Types of Hepatitis Infection based on Strains II-52
• Hepatitis A Virus (HAV) Infection II-52
• Hipatitis B Virus II-52
• Hepatitis B Virus (HBV) Infection II-52
• Treatments Available for Chronic HBV Infection II-52
• Vaccines Dominates the Category II-52
• Antiviral Drugs Available II-53
• Hepatitis C Virus (HCV) Infection II-53
• Treatments Available for Chronic Hepatitis C Infection II-53
• Products in Pipeline II-54
• Some Alternative Treatments II-54
• Hepatitis D Virus (HDV) Infection II-54
• Hepatitis E Virus (HEV) Infection II-55
• Herpes Simplex Virus (HSV) Infection II-55
• HSV-1 Infection II-55
• HSV-2 Infection II-56
• Neonatal Herpes Simplex Infection II-56
• Treatments Available for HSV Infection II-56
• Table Containing Major HSV Drugs along with their Patent Expiry Dates II-56
• HSV Antivirals Available in the Market II-57
• Treatments for Opthalmic Viral Infections II-57
• Cytovene (Ganciclovir) II-57
• Vistide (Cidofovir) II-57
• Foscavir (Foscarnet) II-57
• Vaccines Against HSV Infection II-58
• Respiratory Viruses Infections II-58
• Influenza Virus II-58
• Influenza A Virus II-59
• Avian Flu II-59
• Influenza - Brief History II-59
• Transmission of Influenza Infection II-59
• Treatments for Respiratory Viruses II-59
• Influenza Vaccines II-60
• Respiratory Syncytial Virus (RSV) Infection II-60
• Other Respiratory Viruses II-61
• Treatments for RSV and other Respiratory Viral Infections II-61
• Human Papilloma Virus (HPV) II-61
• Treatments Available for HPV Infection II-61
• Other Types of Viral Diseases II-62
• Treatment Options Available for Other Types of Viral Diseases II-62
• Overview of Antiviral Vaccines II-62

7. International Organizations Supporting Preventative

• and Treatment Programs for Viral Infections II-64
• UNHCR II-64
• UNICEF II-64
• WFP II-64
• UNDP II-64
• UNPF II-65
• UNODC II-65
• ILO II-65
• UNESCO II-65
• WHO II-65
• World Bank II-66
• National AIDS Trust II-66

8. Product Developments and Launches II-67

• Bristol-Myers Unveils Baraclude in India II-67
• Chinese and US Researchers Together Develop Purified Antiviral Compounds II-67
• Celldex to Develop a Fusion Protein CDX 2401 II-67
• PDSC Launches a Germicidal Disinfectant, Medic Kleen II-67
• REPLICor to Develop Antiviral Drugs II-67
• Valeant Pharmaceuticals to Develop Viramidine(R) II-68
• Biota Discovers a New Group of Antiviral Drugs against RSV II-68
• Serum Launches Q-Vac, a Combination Vaccine II-68
• Chongqing Jiachen to Produce Hepatitis B Vaccine II-68
• IIL Decides to Roll Out Five Vaccines in Indian Market II-68
• Shanta Biotechnics to Foray into US Markets with AlphaFeto and Shanvac B II-69
• GSK Launches Hepsera for Chronic Hepatitis B II-69
• Viral Therapeutics Takes Over Development Rights to Recombinant Human Protein II-69
• Biota Inc Introduces New AZT Nucleotide Mimic Drug for HIV/AIDS II-69
• SciGen Ltd Introduces Sci-B-Vac Vaccine for Hepatitis B in Hong Kong II-69
• Aurobindo Pharma Ltd Launches Indivex and Stavex Anti-HIV Drugs II-70
• Trimeris and Roche Collaboratively Develops Two Fusion Inhibitors II-70

9. Recent Industry Activity II-71

• Adventrx Takes Over SD Pharmaceuticals II-71
• Nutra Pharma to Acquire ReceptoPharm II-71
• Dynavax Acquires German Rhein Biotech II-71
• Barrier Acquires Rights to Market Denavir from Norvartis II-71
• Chimerix Acquires Leroy Townsend Library of Lead Drug Candidates II-71
• Sareum Collaborates with Idenix to Develop Antivirals II-72
• CSIRO Collaborates with Bath University to Create an Oral Antiviral Agent II-72
• GlaxoSmithKline and Shionogi to Co-Develop HIV Drugs II-72
• Inovio Biomedical Corporation Enters into an Agreement with Tripep AB II-72
• Roche Partners with Trimeris to Develop HIV Fusion Inhibitor Drugs II-73
• Pfizer and Monogram Execute a Non-Exclusive Collaboration II-73
• Novartis Enters into an Agreement with Human Genome Sciences II-73
• Medivir Inks Licensing Deal with Tibotec for HBV and HIV Drugs II-73
• Boehringer to Enhance its Canadian Antiviral Research Center II-74
• GSK Receives Pediatric Extension of Hevrix Vaccine in the US II-74
• GSK Completes Phase II Clinical Trial on Promacta II-74
• Schering-Plough Undertakes Clinical Trials on Some Hepatitis Products II-74
• Gilead Sciences and Merck Conducts Clinical Trials (Phase I / II) on HIV Integrase Inhibitor II-74
• Vertex to Start Phase IIb Trials for VX-950 II-74
• Schering-Plough Starts Phase II Trials for SCH 503034 II-75
• Panacos Pharmaceuticals Initiates Phase 2b Studies on Bevirimat II-75
• Immune Response Corporation Initiates IR103 Phase II Trial II-75
• Health Enhancement Products Inc to Conduct ProAlgaZyme Clinical Trial II-75
• Novartis Secures FDA Approval for Famvir II-75
• Novelos Therapeutics, Inc Gains FDA Acceptance of INDA for NOV-205 II-76
• Gilead Sciences and Bristol-Myers-Squibb Obtains FDA License for Atripla II-76
• Tibotec Obtains FDA Approval for Darunavir II-76
• Amazon Receives Consent for Phase I/II Trials for AMZ0026 II-76
• MedImmune Applies for Supplemental License for CAIV-T II-77
• FermaVir Pharmaceuticals Obtains FDA Approval for Further Studies on Antiviral Drug Candidate II-77
• Abbott Obtains FDA Assent for ABBOTT PRISM® and PRISM® Blood Screening II-77
• Abbott Receives Authorization from European Commission to Market Kaletra® II-77
• Schering-Plough Receives Marketing Approval for PEG-INTRON® and REBETOL® Drugs II-77
• Idenix and Novartis Submit Drug Application to European Regulators for Telbivudine II-78
• Merck Obtains FDA Approval for Marketing GARDASIL® Vaccine II-78
• Merck's GARDASIL Vaccine Gets CHMP's Positive Opinion II-78
• Boehringer Ingelheim Demonstrates the Clinical Trial Results of Aptivus® Capsules II-78
• GlaxoSmithKline Demonstrates Results for H5N1 Pandemic Flu Vaccine Clinical Trials II-79
• GlaxoSmithKline Minimizes Prices of HIV Drugs in Poor Countries II-79
• Donations Rises for AIDS Orphanage in South Africa II-79
• FDA to Ban the Usage of Human Antiviral Drugs for Influenza Treatment in Poultry II-79
• Third Wave Withdraws Lawsuit against Digene Relating to Patent on HPV Drug II-80
• Roche Files Suit against Ranbaxy to Restrain Launch of Antiviral Generic Drug II-80
• Dainippon Pharmaceutical to Merge with Sumitomo Pharmaceuticals II-80
• Abbott and OraSure Enter into Agreement II-80
• Hemispherx Biopharma Signs a Research Agreement with Defence R&D Canada II-80
• LUPIN and Cornerstone Sign Licensing Agreement to Develop Anti-Infective Product II-81
• Trimeris Inc Enters into Collaborative Agreement with ChemBridge Research Laboratories II-81
• Corixa Corporation Collaborates with Lorantis II-81
• Takeda Enters into HPV Collaborative Agreement with 3M II-81
• MedImmune Inks Collaborative Licensing Agreement with Biota II-82
• Pharmasset Enters into License Agreement with Bukwang Pharm II-82
• Chiron and Enanta Pharmaceuticals Enter into HCV PI Development Agreement II-82
• Gilead Sciences Enters into JTK-303 License Agreement with Japan Tobacco II-82
• Alnylam and Isis Enter into Licensing Deal with Stanford University II-83
• Gen-Probe and F. Hoffmann-La Roche Enter into an Agreement II-83
• SciGen Limited Enters into Hepatitis B Vaccine Distribution Agreement with Berna Biotech AG II-83
• GSK Receives Supply Order for Relenza from Governments of Three Countries II-84
• Bristol-Myers to Establish Production Facility in China II-84
• Koronis Initiates Phase 1b Trial for KP-1461 Antiviral II-84
• Gilead Initiates Phase III Clinical Trials for Tenofovir II-84
• Vaccine Research Center Initiates Phase II Trials onAdenovector II-84
• Aethlon Medical Instigates Clinical Trials of HCV II-85
• Hemispherx Biopharma Initiates Alferon LDO Clinical Trials II-85
• Bristol-Myers and Merck Provide IPM with License to Develop HIV Vaccines II-85
• Hi-Tech's Acyclovir Oral Suspension Secures FDA Approval II-85
• Bristol-Myers Squibb Gains FDA Approval for the company's Entecavir II-85
• Corixa's Fendrix® Vaccine Receives European Approval II-86
• Calypte Biomedical's HIV-1 Urine EIA Screening Test Receives FDA Approval II-86
• Gilead Sciences's Truvada® Receives Marketing Authorization II-86
• Abbott Receives FDA Approval to Formulate Kaletra in Tablet Form II-86
• Boehringer Ingelheim Receives EU Approval to Market Aptivus II-86
• Boehringer Ingelheim Secures FDA Approval to Market Aptivus II-87
• SciClone Releases Poster Presentation of Zadaxin® Triple Therapy II-87
• GlaxoSmithKline Discloses Clinical Findings for Brecanavir II-87
• Abbott and Celera Secure CE Mark Certification for PCR Test II-87
• Gilead Sciences Cuts Prices for Truvada and Viread for Developing Nations II-87
• Gilead Sued Roche for not Properly Marketing Tamiflu and Receives Damage Payment II-88
• MGI PHARMA to Purchase Zycos II-88
• Benitec Ltd Acquires Avocel Inc II-88
• ID Biomedical Takes Over Vaccine Business of Shire II-88
• SGX Forms Alliance with Roche to Develop New Antivirals II-89
• Epimmune and Innogenetics Extend Collaboration Agreement II-89
• Nucleonics and Novosom Collaborate to Develop New Antivirals II-89
• Gilead Sciences and Achillion Pharmaceuticals Sign Licensing Agreement II-89
• ZymoGenetics Licenses Drug Development Rights to Novo Nordisk II-90
• Cubist and XTL Sign Development Agreement II-90
• Sunesis and Merck Signs Research Agreement II-90
• CytoGenix Files Pre-IND Brief with the FDA II-90
• ViroPharma Signs Licensing Agreement with Schering-Plough II-91
• Hemispherx Inks Agreement with GMC for Development and Commercialization of HIV Antivirals II-91
• DNA-C and NYVAC Combination AIDS Vaccine To Enter Clinical Trial Stage II-91
• GlaxoSmithKline Plc Reduces Anti-AIDS Treatment Prices in Poor Countries II-91
• Gilead Acquires Triangle Pharmaceuticals II-92
• Micrologix Acquires Antivirals Portfolio of Origenix II-92
• Roche Acquires HPV Patent Portfolio from Pasteur Institute II-92
• Johnson & Johnson Enters into an Agreement to Acquire Tibotec-Virco NV II-92
• USL Signs Licensing Agreement with Novactyl II-92
• Micrologix Biotech and Hybridon Signs Collaborative Licensing Agreement II-93
• Novartis Acquires a Portfolio of Antivirals from SmithKline Beecham II-93
• Biota Inc's Bird Flu Drug Relenza Receives FDA Approval II-93

10. Focus on Select Key Players II-94

• Abbott Laboratories (USA) II-94
• Boehringer Ingelheim (Germany) II-94
• Bristol-Myers Squibb (USA) II-94
• Gilead Sciences (USA) II-95
• GlaxoSmithKline Plc. (UK) II-95
• Hoffmann-La Roche (Switzerland) II-96
• Merck & Co. (USA) II-97
• Novartis AG (Switzerland) II-97
• Pfizer Inc. (USA) II-98
• Schering-Plough Corp. (USA) II-98

11. Global Market Perspective II-99

• Table 26: World Recent Past, Current & Future Analysis for Antivirals by Geographic Region - US, Japan, Europe and Rest of World (excluding Japan) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) II-99
• Table 27: World Recent Past, Current & Future Analysis for Antivirals by Product Segment - HIV Antivirals (RTIs {NRTIs and NNTRIs}, PIs and Other HIV Antivirals), Hepatitis B & C Antivirals (Hepatitis C Antivirals and Hepatitis B Antivirals), HSV Antivirals, Influenza Antivirals, RSV Antivirals, HPV Antivirals, and Other Antivirals Independently Analyzed by Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) II-100
• Table 28: World 10-Year Perspective for Antivirals by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World (excluding Japan) for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart) II-101
• Table 29: World 10-Year Perspective for Antivirals by Product Segment - Percentage Breakdown of Dollar Sales for HIV Antivirals (RTIs {NRTIs and NNTRIs}, PIs and Other HIV Antivirals), Hepatitis B & C Antivirals (Hepatitis C Antivirals and Hepatitis B Antivirals), HSV Antivirals, Influenza Antivirals, RSV Antivirals, HPV Antivirals, and Other Antivirals for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart) II-102
• Table 30: World Recent Past, Current & Future Analysis for HIV Antivirals by Geographic Region - US, Japan, Europe and Rest of World (excluding Japan) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) II-103
• Table 31: World 10-Year Perspective for HIV Antivirals by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World (excluding Japan) Markets for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart) II-103
• Table 32: World Recent Past, Current & Future Analysis for Hepatitis B & C Antivirals by Geographic Region - US, Japan, Europe and Rest of World (excluding Japan) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) II-104
• Table 33: World 10-Year Perspective for Hepatitis B & C Antivirals by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World (excluding Japan) Markets for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart) II-104
• Table 34: World Recent Past, Current & Future Analysis for Hepatitis C Antivirals by Geographic Region - US, Japan, Europe and Rest of World (excluding Japan) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) II-105
• Table 35: World 10-Year Perspective for Hepatitis C Antivirals by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World (excluding Japan) Markets for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart) II-105
• Table 36: World Recent Past, Current & Future Analysis for Hepatitis B Antivirals by Geographic Region - US, Japan, Europe and Rest of World (excluding Japan) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) II-106
• Table 37: World 10-Year Perspective for Hepatitis B Antivirals by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World (excluding Japan) Markets for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart) II-106

III. MARKET

1. The United States III-1

• A. Market Analysis III-1
• Infectious Disease Drugs Market in the US III-1
• Table 38: Infectious Disease Drugs Market by Class in the US: 2005 Percentage Share Breakdown by Type for Quinolones, Penicillins, Macrolides, Antifungals, Cephalosporins, Antivirals, Tetracyclines, Erythromycins and Other Therapies in US$ million (includes corresponding Graph/Chart) III-1
• Antivirals Market Perspective in the US III-1
• HIV Antivirals Dominate the Antiviral Therapies Market in the US, followed by the Hepatitis B & C Antivirals Class III-1
• Table 39: Antivirals Market by Type in the US: 2006 Percentage Share Breakdown for HIVAntivirals, Hepatitis B & C Antivirals, and Other Antivirals (includes corresponding Graph/Chart) III-2
• Combivir Dominates the Reverse Transcriptase Inhibitors Market in the US III-2
• Table 40: Reverse Transcriptase Inhibitors Market by Brand Type in the US: 2005 Percentage Share Breakdown for Combivir, Zerit, Epivir, Sustiva, Viramune, Ziagen, Videx, Retrovir and *Others (includes corresponding Graph/Chart) III-2
• Table 41: Leading Players in the HIV Reverse Transcriptase Inhibitors (RTIs) Market in the US: 2005 Percentage Share Breakdown for Glaxo SmithKline, Bristol-Myers Squibb and *Others (includes corresponding Graph/Chart) III-3
• Viracept Dominates the Protease Inhibitors Market in the US III-3
• Table 42: Protease Inhibitors Market by Brand Type in the US: 2005 Percentage Share Breakdown for Viracept, Crixivan, Norvir, Fortovase, Agenerase and Invirase (includes corresponding Graph/Chart) III-3
• Table 43: Leading Players in the HIV Protease Inhibitors (PIs) Market in the US: 2005 Percentage Share Breakdown for Abbott Laboratories, Pfizer and *Others (includes corresponding Graph/Chart) III-3
• Hepatitis B Infection Prevalence in the US III-3
• Hepsera Dominates the Oral Hepatitis B Antivirals Market III-4
• Table 44: Leading Brands in the Oral Hepatitis B Antivirals Market in the US: 2006 Percentage Share Breakdown for Hepsera, Epivir HBV and Baraclude (includes corresponding Graph/Chart) III-4
• New Emerging Therapies for HBV Infection in the US III-4
• Emerging Hepatitis B Infection Antivirals in Phase II Clinical Trials in the US III-5
• Emerging Hepatitis B Infection Antivirals in Phase I Clinical Trials in the US III-5
• Hepatitis C Antivirals Market in the US III-5
• Table 45: Leading Players in the Hepatitis C Antivirals Market in the US: 2005 Percentage Share Breakdown for Schering Plough and *Others III-6
• Table 46: Leading Brands in the Interferon Hepatitis C Antivirals Market in the US: 2006 Percentage Share Breakdown for Pegasys, PEG Intron, Copegus and Rebetol (includes corresponding Graph/Chart) III-6
• HSV Antivirals in the US III-6
• Table 47: Leading Players in the HSV Antivirals Market in the US: 2005 Percentage Share Breakdown for Glaxo SmithKline, Generics and *Others (includes corresponding Graph/Chart) III-6
• Influenza Antivirals Market in the US III-7
• Emerging Influenza Antivirals in the Clinical Development Stage in the US III-7
• TIV Dominates the US Influenza Vaccines Market III-7
• Table 48: Influenza Vaccines Market in the US: 2006 Percentage Share Breakdown by Vaccine Type for Treated (Killed) Influenza Vaccine (TIV) and Live Attenuated Influenza Vaccine (LAIV) III-7
• Fluzone Rules the Roost in the Influenza Vaccines Market III-7
• Table 49: Influenza Vaccines Market in the US: 2006 Percentage Share Breakdown by Vaccine Brand for Fluzone, Fluvirin, Fluarix and FluMist (includes corresponding Graph/Chart) III-8
• Table 50: Leading Players in the Influenza Antivirals Market in the US: 2005 Percentage Share Breakdown for Roche and *Others III-8
• HIV/AIDS Prevalence in the US III-8
• Homosexual Males Emerges as a Significant Risk Group for HIV Infections in the US III-9
• Table 51: Diagnosis of HIV/AIDS among Adult and Adolescent Males in the US: 2005 Percentage Share Breakdown by Transmission Category for Homosexual Contact, Heterosexual Contact, Injecting Drug User (IDU), Homosexual Contact & IDU and Others (includes corresponding Graph/Chart) III-9
• Table 52: Ethnic Group Distribution of HIV/AIDS Cases Among Men with Homosexual Contacts in the US: 2005 Percentage Share Breakdown for Whites, African Americans, Latin Americans, Asian/Pacific Islander and American Indian/Alaska Native (includes corresponding Graph/Chart) III-10
• Women, a High Risk Group for HIV/AIDS in the US III-10
• Table 53: AIDS Cases Reported in the US Among Females 13 and Older: 2005 Percentage Share Breakdown by Ethnic Community for African American Women, Latin American Women, White Women and Others (includes corresponding Graph/Chart) III-10
• Table 54: Diagnosis of HIV/AIDS among Adult and Adolescent Females in the US: 2005 Percentage Share Breakdown by Transmission Category for Heterosexual Contact, Injecting Drug User (IDU) and Others (includes corresponding Graph/Chart) III-10
• African Americans, the Leading High Risk Ethnic Group for HIV Infection in the US III-11
• Table 55: Individuals Living with AIDS in the US: 2005 Percentage Share Breakdown by Ethnic Community for African Americans, Whites, Latin Americans and Others (includes corresponding Graph/Chart) III-11
• Latinos, the Second Major Ethnic Risk Group for HIV Infection in the US III-11
• Zidovudine (ZDV) Emerges as a Major Drug to Prevent Mother-to-Child Transmission of HIV Infection III-11
• An Overview of Sexually Transmitted Diseases (STDs) in the US III-11
• Regulatory Environment for HIV/AIDS in the US III-12
• Product Launches III-12
• Strategic Corporate Developments III-14
• Focus on Key Players III-27
• 3M III-27
• Abbott Laboratories III-27
• Amazon Biotech III-28
• Bristol-Myers Squibb III-28
• FermaVir Pharmaceuticals III-29
• Gilead Sciences III-29
• Hemispherx Biopharma III-29
• MedImmune Inc. III-30
• Merck & Co. III-30
• Novartis Pharmaceuticals III-30
• Novelos Therapeutics III-31
• Panacos Pharmaceuticals III-31
• Pfizer Inc. III-31
• Pharmasset III-31
• Schering-Plough Corporation III-32
• B. Market Analytics III-32
• Table 56: US Recent Past, Current & Future Analysis for Antivirals Market Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-32
• Table 57: US Recent Past, Current & Future Analysis for HIV Antivirals by Product Segment - RTIs (NRTIs and NNTRIs), PIs and Other HIV Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-33
• Table 58: US 10-Year Perspective for HIV Antivirals by Product Segment - Percentage Breakdown of Value Sales for RTIs (NRTIs and NNTRIs), PIs and Other HIV Antivirals for the Years 2000, 2006 & 2010 (includes corresponding Graph/Chart) III-33
• Table 59: US Recent Past, Current & Future Analysis for Hepatitis B & C Antivirals by Product Segment - Hepatitis C Antivirals and Hepatitis B Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-34
• Table 60: US 10-Year Perspective for Hepatitis B & C Antivirals by Product Segment - Percentage Breakdown of Value Sales for Hepatitis C Antivirals and Hepatitis BAntivirals for the Years 2000, 2006 & 2010 III-34

2. Japan III-35

• A. Market Analysis III-35
• Japanese Antivirals Market Perspective III-35
• HIV Infection Prevalence in Japan III-35
• Hepatitis B & C Antivirals Dominate the Japanese Antivirals Market III-35
• Japan, the Second Largest Market for Hepatitis C Infection in the World III-35
• Table 61: Leading Drug Brands for Hepatitis C Antivirals in Japan: 2005, 2006 and 2008E Percentage Share Breakdown for PEG-Intron, Pegasys, Intron A, Advaferon, Sumiferon, Feron and Others (includes corresponding Graph/Chart) III-36
• Product Launch III-36
• Strategic Corporate Developments III-36
• Focus on Key Players III-37
• Daiichi Pharmaceutical Co. III-37
• Japan Tobacco III-38
• B. Market Analytics III-38
• Table 62: Japanese Recent Past, Current & Future Analysis for Antivirals Market Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-38
• Table 63: Japanese Recent Past, Current & Future Analysis for HIV Antivirals Market Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-39
• Table 64: Japanese Recent Past, Current & Future Analysis for Hepatitis B & C Antivirals by Product Segment - Hepatitis C Antivirals and Hepatitis B Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-39
• Table 65: Japanese 10-Year Perspective for Hepatitis B & C Antivirals by Product Segment - Percentage Breakdown of Value Sales for Hepatitis C Antivirals and Hepatitis B Antivirals for the Years 2000, 2006 & 2010 III-39

3. Europe III-40

• A. Market Analysis III-40
• France - The Largest and the Fastest Growing Market for Antivirals III-40
• HIV Therapy Dominates the Antivirals Market III-40
• Table 66: Antivirals Market by Type in Europe: 2006 Percentage Share Breakdown for HIV Antivirals, Hepatitis B & C Antivirals, and Other Antivirals (includes corresponding Graph/Chart) III-40
• HIV/AIDS Prevalence in Europe III-41
• HIV/AIDS Statistics in Western Europe III-41
• UK Dominates the Market for Western Europe for HIV Infection III-41
• Table 67: Diagnosis of HIV Infection among Adults in Western Europe: 2005 Percentage Share Breakdown by Region for UK, Portugal, **France, Germany, The Netherlands, *Italy, Belgium, Switzerland and Others (includes corresponding Graph/Chart) III-41
• HIV/AIDS Statistics in Central Europe III-42
• Poland Dominates the Market for Central Europe for HIV Infection III-42
• Table 68: Diagnosis of HIV Infection among Adults in Central Europe: 2005 Percentage Share Breakdown by Region for Poland, Romania, Turkey, Serbia & Montenegro, Czech Republic, Hungary, Bulgaria and Others (includes corresponding Graph/Chart) III-42
• HIV/AIDS Statistics in Eastern Europe III-42
• Russia Dominates the Market for Eastern Europe for HIV Infection III-42
• Table 69: Diagnosis of HIV Infection among Adults in Eastern Europe: 2005 Percentage Share Breakdown by Region for Russia, *Ukraine, Uzbekistan, Belarus, Estonia, Kazakhstan, Republic of Moldova, Latvia and Others (includes corresponding Graph/Chart) III-43
• Herpes Antivirals III-43
• Strategic Corporate Developments III-43
• B. Market Analytics III-46
• Table 70: European Recent Past, Current & Future Analysis for Antivirals by Geographic Region - France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-46
• Table 71: European 10-Year Perspective for Antivirals by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain and Rest of Europe for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart) III-46
• Table 72: European Recent Past, Current & Future Analysis for HIV Antivirals by Product Segment - RTIs (NRTIs and NNTRIs), PIs and Other HIV Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-47
• Table 73: European 10-Year Perspective for HIV Antivirals by Product Segment -Percentage Breakdown of Value Sales for RTIs (NRTIs and NNTRIs), PIs and Other HIV Antivirals for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart) III-47
• Table 74: European Recent Past, Current & Future Analysis for Hepatitis B & C Antivirals by Product Segment - Hepatitis C Antivirals and Hepatitis B Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-48
• Table 75: European 10-Year Perspective for Hepatitis B & C Antivirals by Product Segment- Percentage Breakdown of Value Sales for Hepatitic C Antivirals and Hepatitis B Antivirals for Years 2000, 2006 & 2010 III-48

3a. France III-49

• A. Market Analysis III-49
• France the Largest and Fastest Growing Antivirals Market in Europe III-49
• Strategic Corporate Developments III-49
• B. Market Analytics III-49
• Table 76: French Recent Past, Current & Future Analysis for Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-49

3b. Germany III-50

• A. Market Analysis III-50
• Germany the Second Largest and Fastest Growing Antivirals Market in Europe III-50
• Strategic Corporate Developments III-50
• Focus on Key Player III-51
• Boehringer Ingelheim III-51
• B. Market Analytics III-51
• Table 77: German Recent Past, Current & Future Analysis for Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-51

3c. Italy III-52

• A. Market Analysis III-52
• Strategic Corporate Developments III-52
• B. Market Analytics III-52
• Table 78: Italian Recent Past, Current & Future Analysis for Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-52

3d. The United Kingdom III-53

• Market Analysis III-53
• UK the Third Largest Market for Antivirals in Europe III-53
• HIV/AIDS Prevalence in the UK III-53
• Table 79: Diagnosis of HIV Infection among Individuals in the UK: 2005 Percentage Share Breakdown by Ethnic Community for Whites, Black- Africans, Black-Caribbeans and Others (includes corresponding Graph/Chart) III-53
• Table 80: Diagnosis of AIDS among Adult Males in the UK: 2005 Percentage Share Breakdown by Transmission Category for Homosexual Contact, Heterosexual Contact, Injecting Drug Use (IDU), Blood/Tissue Transfer or Blood Factor and Others (includes corresponding Graph/Chart) III-54
• Table 81: Diagnosis of AIDS among Adult Females in the UK: 2005 Percentage Share Breakdown by Transmission Category for Heterosexual Contact, Injecting Drug Use (IDU), Mother-to-Child Transfer, Blood/Tissue Transfer or Blood Factor and Others (includes corresponding Graph/Chart) III-54
• Table 82: Diagnosis of HIV Infection in People in the UK: 2005 Percentage Share Breakdown by Region for England, Scotland, Wales and North Ireland (includes corresponding Graph/Chart) III-54
• Drug Resistant HIV Strains Rising in the UK III-54
• Rise in Sexually Transmitted Diseases Pose Health Risks III-54
• Strategic Corporate Developments III-55
• Focus on Key Player III-55
• GlaxoSmithKline PLC III-55
• B. Market Analytics III-56
• Table 83: UK Recent Past, Current & Future Analysis for Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-56

3e. Spain III-57

• A. Market Analysis III-57
• B. Market Analytics III-57
• Table 84: Spanish Recent Past, Current & Future Analysis for Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-57
• 3f. Rest of Europe III-58
• A. Market Analysis III-58
• Russia III-58
• Acute Supply Shortage of AIDS drugs Risks the Life of Many People in Russia III-58
• Strategic Corporate Developments III-58
• Focus on Key Players III-60
• Hoffmann-La Roche (Switzerland) III-60
• Novartis AG (Switzerland) III-61
• B. Market Analytics III-61
• Table 85: Rest of Europe Recent Past, Current & Future Analysis for Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-61

4. Rest of World III-62

• A. Market Analysis III-62
• Canada III-62
• HIV/AIDS Prevalence in Canada III-62
• Table 86: Diagnosis of HIV Infection among Adult Males in Canada: 2005 Percentage Share Breakdown by Transmission Category for Homosexual Contact, Heterosexual Contact, Injecting Drug Use (IDU), Homosexual Contact & IDU, Infection through Blood/Blood Products and Others (includes corresponding Graph/Chart) III-62
• Table 87: Diagnosis of HIV Infection among Adult Females in Canada: 2005 Percentage Share Breakdown by Transmission Category for Heterosexual Contact, Injecting Drug Use (IDU), Infection through Blood/Blood Products and Others (includes corresponding Graph/Chart) III-63
• Table 88: Diagnosis of AIDS among Adult Males in Canada: 2005 Percentage Share Breakdown by Transmission Category for Homosexual Contact, Heterosexual Contact, Injecting Drug Use (IDU), Homosexual Contact & IDU and Others (includes corresponding Graph/Chart) III-63
• Table 89: Diagnosis of AIDS among Adult Females in Canada: 2005 Percentage Share Breakdown by Transmission Category for Heterosexual Contact, Injecting Drug Use (IDU) and Others (includes corresponding Graph/Chart) III-63
• Table 90: Individuals Living with AIDS in Canada: 2005 Percentage Share Breakdown by Ethnic Community for Whites, Aboriginals, Blacks, South Asian/West Asian/Arab, Asians and Others (includes corresponding Graph/Chart) III-64
• Hepatitis C Infection Prevalence in Canada III-64
• Asia-Pacific III-64
• HIV/AIDS Prevalence in Asia III-64
• HIV Infection Among Males Rising III-64
• Australia III-65
• HIV/AIDS Prevalence in Australia III-65
• Table 91: Diagnosis of HIV Infections in Australia: 2005 Percentage Share Breakdown by Region for New South Wales, Victoria, Queensland, Western Australia, South Australia, Australian Capital Territory and Others (includes corresponding Graph/Chart) III-65
• Hepatitis C Infection Prevalence in Australia III-65
• Table 92: Sources of Hepatitis C Infection Transmission in Australia: 2005 Percentage Share Breakdown by Transmission Category for Injecting Drug Use (IDU), Blood Transfusion/Medical, Tattoos/Piercing, Sexual Contact and Others (includes corresponding Graph/Chart) III-66
• Bangladesh III-66
• HIV/AIDS Prevalence in Bangladesh III-66
• Cambodia III-66
• HIV/AIDS Prevalence in Cambodia III-66
• China III-66
• Antivirals Market in China III-66
• China Presents a Major Market for Hepatitis B Therapies III-67
• HIV/AIDS Prevalence in China III-67
• Hong Kong III-67
• HIV/AIDS Prevalence in Hong Kong III-67
• India III-68
• Hepatitis B Vaccines Market in India III-68
• Table 93: Hepatitis B Vaccine Market in India: 2005 Percentage Share Breakdown by Player for Shantha Biotech, Glaxo SmithKline and Others (includes corresponding Graph/Chart) III-68
• HIV/AIDS Prevalence in India III-68
• Table 94: AIDS Cases Diagnosed in India: 2005 Percentage Share Breakdown by Gender for Males and Females III-69
• Table 95: Diagnosis of HIV/AIDS Cases in India: 2005 Percentage Share Breakdown by Transmission Category for Sexual Contact, Mother-to-Child Transfer, Injecting Drug Use (IDU), Blood and Blood Products, and Others (includes corresponding Graph/Chart) III-69
• Table 96: Diagnosis of AIDS Cases in India: 2005 Percentage Share Breakdown by Geographic Region for Tamil Nadu, Maharashtra, Andhra Pradesh, Karnataka, Manipur, West Bengal, Kerala, Madhya Pradesh, Uttar Pradesh, Rajasthan and Others (includes corresponding Graph/Chart) III-69
• India Emerging as a Major Market for HIV-Infected People in the World III-70
• Table 97: Diagnosis of HIV Infection in India: 2005 Percentage Share Breakdown by Sub-Population for General Population, STD Patients, Injecting Drug Users (IDUs), Children and Female Sex Workers (FSWs) (includes corresponding Graph/Chart) III-70
• Organizations Active in Executing HIV/AIDS Control and Prevention Programs III-70
• Table 98: Institutional Funding for HIV/AIDS Control Programs in India: 2005 Percentage Share Breakdown by Funding Organization for Public Bodies, Bilateral Organizations, World Bank, Multilateral Organizations and Global Funds (includes corresponding Graph/Chart) III-71
• India Steps Up Infrastructure Development to Control
• and Prevent the Spread of Viral Infections III-71
• New Treatment Options to Fight Against HIV Infection III-71
• AIDS Control Programs for Rural Youths in India III-72
• Indonesia III-72
• HIV/AIDS Prevalence in Indonesia III-72
• Myanmar (Burma) III-72
• HIV/AIDS Prevalence in Myanmar III-72
• Nepal III-72
• HIV/AIDS Prevalence in Nepal III-72
• New Zealand III-73
• HIV/AIDS Prevalence in New Zealand III-73
• Pakistan III-73
• HIV/AIDS Prevalence in Pakistan III-73
• Singapore III-73
• HIV/AIDS Prevalence in Singapore III-73
• South Korea III-73
• HIV/AIDS Prevalence in South Korea III-73
• Thailand III-73
• HIV/AIDS Prevalence in Thailand III-73
• Viet Nam III-74
• HIV/AIDS Prevalence in Viet Nam III-74
• Hepatitis B Infection Prevalence in Viet Nam III-74
• Latin America III-74
• HIV/AIDS Prevalence in Latin America III-74
• Table 99: Diagnosis of People Living with HIV/AIDS in Latin America: 2005 Percentage Share Breakdown by Geographic Region for Brazil, Mexico, Colombia, Argentina, Venezuela, Peru, Honduras, Guatemala, El Salvador, Ecuador, Panama, Paraguay and Others (includes corresponding Graph/Chart) III-75
• Table 100: Diagnosis of AIDS Related Deaths in Latin America: 2005 Percentage Share Breakdown by Geographic Region for Brazil, Colombia, Mexico, Venezuela, Peru, Argentina, Honduras, Guatemala, El Salvador, Ecuador, Panama and Others (includes corresponding Graph/Chart) III-75
• HIV/AIDS Prevalence in the Caribbean Region III-76
• Table 101: Diagnosis of People Living with HIV/AIDS in Caribbean: 2005 Percentage Share Breakdown by Geographic Region for Haiti, Dominican Republic, Trinidad and Tobago, Jamaica, Bahamas, Cuba and Barbados (includes corresponding Graph/Chart) III-76
• Table 102: Diagnosis of AIDS Related Deaths in Caribbean: 2005 Percentage Share Breakdown by Geographic Region for Haiti, Dominican Republic, Trinidad and Tobago, Jamaica and Others (includes corresponding Graph/Chart) III-77
• Africa III-77
• HIV/AIDS Prevalence in Sub-Saharan Africa III-77
• Table 103: Diagnosis of People Living with HIV/AIDS in Sub-Saharan Africa: 2005 Percentage Share Breakdown by Geographic Region for South Africa, Nigeria, Mozambique, Zimbabwe, United Republic of Tanzania, Kenya, Ethiopia, Zambia, Democratic Republic of Congo, Uganda and Others (includes corresponding Graph/Chart) III-77
• Table 104: Diagnosis of AIDS Related Deaths in Sub-Saharan Africa: 2005 Percentage Share Breakdown by Geographic Region for South Africa, Nigeria, Zimbabwe, Mozambique, United Republic Of Tanzania, Kenya, Ethiopia, Zambia, Uganda, Malawi and Others (includes corresponding Graph/Chart) III-78
• Table 105: Diagnosis of AIDS Related Orphans in Sub-Saharan Africa: 2005 Percentage Share Breakdown by Geographic Region for South Africa, Kenya, United Republic Of Tanzania, Zimbabwe, Uganda, Nigeria, Ethiopia, Zambia, Democratic Republic of Congo, Malawi and Others (includes corresponding Graph/Chart) III-78
• South Africa III-79
• Television Exposures Induces Healthy Lifestyle Changes Among People to Combat HIV/AIDS Epidemic III-79
• HIV/AIDS Prevalence in South Africa III-79
• Middle East III-79
• HIV/AIDS Prevalence in Middle East III-79
• Product Launches III-80
• Strategic Corporate Developments III-81
• Focus on Select Players III-85
• Bukwang Pharm (South Korea) III-85
• Benitec Limited (Australia) III-85
• B. Market Analytics III-85
• Table 106: Rest of World Recent Past, Current & Future Analysis for Antivirals Market Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-85
• Table 107: Rest of World Recent Past, Current & Future Analysis for Hepatitis B & C Antivirals by Product Segment - Hepatitis C Antivirals and Hepatitis B Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-86
• Table 108: Rest of World 10-Year Perspective for Hepatitis B & C Antivirals by Product Segment - Percentage Breakdown of Value Sales for Hepatitis C Antivirals and Hepatitis B Antivirals for the Years 2000, 2006 & 2010 (includes corresponding Graph/Chart) III-86
• Table 109: Rest of World 10-Year Perspective for Hepatitis B & C Antivirals by Product Segment - Percentage Breakdown of Value Sales for Hepatitis C Antivirals and Hepatitis B Antivirals for the Years 2000, 2006 & 2010 III-86

IV. COMPETITION

• 1. 3M Company (USA) IV-1
• Table 110: First Quarter Sales Analysis: 2005-2006 (In US$ billion) IV-5
• Table 111: First Quarter Sales Analysis by Segment: 2005-2006 (In US$ billion) IV-5
• Table 112: Annual Sales Analysis: 2004-2005 (In US$ billion) IV-5
• Table 113: Annual Sales Analysis by Segment: 2004-2005 (In US$ billion) IV-5
• Table 114: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ billion) IV-6
• 3M Pharmaceuticals (USA) IV-14
• 2. Abbott Laboratories (USA) IV-15
• Table 115: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-17
• Table 116: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million) IV-17
• Table 117: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ million) IV-17
• Table 118: Annual Sales Analysis: 2004-2005 (In US$ million) IV-18
• Table 119: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-18
• Table 120: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-18
• Table 121: Annual sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-18
• 3. Achillion Pharmaceuticals, Inc. (USA) IV-27
• 4. Adithya Pharmaceuticals Pvt., Ltd. (India) IV-27
• 5. Adventrx Pharmaceuticals, Inc. (USA) IV-28
• 6. Aeterna Zentaris, Inc. (Canada) IV-30
• Table 122: Annual Sales Analysis: 2004-2005 (In US$ million) IV-30
• Table 123: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-31
• Table 124: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-31
• Table 125: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-31
• 7. Aethlon Medical, Inc. (USA) IV-33
• 8. Alfacell Corporation (USA) IV-34
• 9. Alnylam Pharmaceuticals, Inc. (USA) IV-36
• Table 126: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-36
• Table 127: Annual Sales Analysis: 2004-2005 (In US$ million) IV-36
• Table 128: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-37
• 10. Amarillo Biosciences (USA) IV-38
• Table 129: Half Yearly Sales Analysis 2005-2006 (H1) (US$ Million) IV-38
• Table 130: Annual Sales Analysis 2004-2005 (US$ Million) IV-38
• 11. Amazon Biotech (USA) IV-41
• 12. Amgen, Inc. (USA) IV-42
• Table 131: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-43
• Table 132: Annual Sales Analysis: 2004-2005 (In US$ million) IV-43
• Table 133: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-43
• 13. Anadys Pharmaceuticals (USA) IV-46
• Table 134: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-47
• Table 135: Annual Sales Analysis: 2004-2005 (In US$ million) IV-47
• Table 136: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-47
• 14. Antigenics, Inc. (USA) IV-48
• Table 137: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-49
• Table 138: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million) IV-49
• Table 139: Annual Sales Analysis: 2004-2005 (In US$ million) IV-49
• 15. Ares Serono (France) IV-52
• 16. Array BioPharma, Inc. (USA) IV-53
• Table 140: Annual Sales Analysis: 2004-2005 (In US$ million) IV-53
• 17. Arrow Pharmaceuticals (Australia) IV-55
• 18. Aspen Pharmacare Holding Ltd. (South Africa) IV-56
• Table 141: Annual Sales Analysis: 2004-2005 (In R million) IV-58
• 19. Astral Pharmaceuticals (India) IV-65
• 20. Astellas Pharma, Inc. (Japan) IV-66
• 21. AstraZeneca PLC (UK) IV-68
• Table 142: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-70
• Table 143: First Quarter Sales Analysis by Geographic Region: 2005-2006 (In US$ million) IV-71
• Table 144: Annual Sales Analysis: 2003-2005 (In US$ million) IV-71
• Table 145: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-71
• 22. Aurobindo Pharma Ltd. (India) IV-80
• Table 146: Annual Sales Analysis: 2004-2005 (In INR million) IV-80
• 23. Avanir Pharmaceuticals (USA) IV-85
• Table 147: Nine Months Sales Analysis: 2005-2006 (Nine Months Ended, June) (In US$ million) IV-86
• Table 148: Nine Months Sales Analysis by Quarter: 2005-2006 (Nine Months Ended, June) (In US$ million) IV-86
• Table 149: Nine Months Sales Analysis by Segment: 2005-2006 (Nine Months ended, June) (In US$ million) IV-86
• Table 150: Annual Sales Analysis: 2004-2005 (In US$ million) IV-86
• Table 151: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-87
• Table 152: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-87
• 24. Bavarian Nordic A/S (Denmark) IV-89
• Table 153: Half Yearly Sales Analysis: 2006-2005 (H1) (In DKK million) IV-90
• Table 154: Annual Sales Analysis: 2004-2005 (In DKK million) IV-90
• 25. Bayer HealthCare AG (Germany) IV-91
• Table 155: Annual Sales Analysis: 2004-2005 (In € million) IV-93
• Table 156: Annual Sales Analysis by Segment: 2004-2005 (In € million) IV-93
• Table 157: Annual Sales Analysis by Geographic Region: 2004-2005 (In € million) IV-93
• 26. Becton Dickinson and Company (USA) IV-97
• Table 158: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-99
• Table 159: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million) IV-99
• Table 160: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ million) IV-99
• Table 161: Annual Sales Analysis: 2004-2005 (In US$ million) IV-99
• 27. Benitec Ltd. (Australia) IV-102
• 28. Biomerieux SA (France) IV-104
• 29. Biomira, Inc. (Canada) IV-107
• 30. Biota Holdings Limited (Australia) IV-108
• Table 162: Annual Sales Analysis: 2005-2006 (In US$ million) IV-108
• 31. Biovail Pharmaceuticals (Canada) IV-109
• 32. Boehringer Ingelheim GmbH (Germany) IV-110
• Roxane Laboratories, Inc. (USA) IV-114
• 33. Bristol-Myers Squibb Company (USA) IV-115
• Table 163: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ billion) IV-117
• Table 164: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ billion) IV-117
• Table 165: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ billion) IV-117
• Table 166: Annual Sales Analysis: 2004-2005 (In US$ billion) IV-117
• Table 167: Annual Sales Analysis by Quarter: 2004-2005 (In US$ billion) IV-117
• Table 168: Annual Sales Analysis by Segment: 2004-2005 (In US$ billion) IV-118
• Table 169: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ billion) IV-118
• 34. Bukwang Pharmaceutical Company Limited (South Korea) IV-123
• 35. Cavidi Tech AB (Sweden) IV-125
• 36. Celldex Therapeutics, Inc. (USA) IV-126
• 37. CEL-SCI Corporation (USA) IV-128
• Table 170: Nine Months Sales Analysis: 2005-2006 (Nine Months Ended, June) (In US$ thousand) IV-129
• Table 171: Nine Months Sales Analysis by Quarter: 2005-2006 (Nine Months Ended, June) (In US$ thousand) IV-129
• Table 172: Annual Sales Analysis: 2004-2005 (In US$ thousand) IV-129
• 38. ChemBridge Research Laboratories, Inc. (USA) IV-131
• 39. Chimerix, Inc. (USA) IV-133
• 40. Chongqing Jiachen Product Manufacturing Co., Ltd. (China) IV-134
• 41. Coley Pharmaceutical Group, Inc. (USA) IV-135
• Table 173: Half-Yearly Sales Analysis: 2006-2005 (H1) (In Can$ thousand) IV-135
• Table 174: Annual Sales Analysis: 2004-2005 (In Can$ thousand) IV-136
• Table 175: Annual Sales Analysis by Quarter: 2005-2004 (In Can$ thousands) IV-136
• 42. Cornerstone BioPharma, Inc. (USA) IV-137
• 43. Cubist Pharmaceuticals, Inc. (USA) IV-139
• Table 176: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-139
• Table 177: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million) IV-140
• Table 178: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ million) IV-140
• Table 179: Annual Sales Analysis: 2004-2005 (In US$ million) IV-140
• Table 180: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-140
• 44. Cytogenix, Inc. (USA) IV-141
• 45. Daiichi Pharmaceutical Co., Ltd. (Japan) IV-142
• Table 181: Annual Sales Analysis: 2004-2005 (In ¥ billion) IV-143
• Table 182: Annual Sales Analysis by Segment: 2004-2005 (In ¥ billion) IV-143
• 46. Dainippon Sumitomo Pharma Company Ltd. (Japan) IV-145
• Table 183: Annual Sales Analysis: 2005-2006 (In ¥ million) IV-146
• 47. Digene Corporation (USA) IV-147
• Table 184: Annual Sales Analysis: 2003-2005 (In US$ million) IV-147
• Table 185: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-148
• 48. E. I. Du Pont De Nemours and Company (USA) IV-150
• Table 186: Annual Sales Analysis: 2004-2005 (In US$ billion) IV-151
• Table 187: Annual Sales Analysis by Quarter: 2004-2005 (In US$ billion) IV-152
• Table 188: Annual Sales Analysis by Segment: 2004-2005 (In US$ billion) IV-152
• Table 189: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ billion) IV-152
• 49. Eli Lilly and Company (USA) IV-155
• Table 190: Half Yearly Sales Analysis: 2004-2005 (H1) (In US$ million) IV-156
• Table 191: Half Yearly Sales Analysis by Segment: 2004-2005 (H1) (In US$ million) IV-157
• Table 192: Half Yearly Sales Analysis by Product: 2004-2005 (H1) (In US$ million) IV-157
• Lilly Research Labs (USA) IV-162
• 50. Enanta Pharmaceuticals, Inc. (USA) IV-163
• 51. Endo Labs (USA) IV-165
• 52. Enzo Diagnostics, Inc. (USA) IV-165
• 53. F. Hoffmann-La Roche Ltd. (Switzerland) IV-166
• Table 193: First Quarter Sales Analysis: 2005-2006 (In CHF billion) IV-167
• Table 194: First Quarter Sales Analysis by Segment: 2005-2006 (In CHF billion) IV-167
• Table 195: Annual Sales Analysis: 2004-2005 (In CHF billion) IV-167
• Roche Laboratories, Inc. (USA) IV-170
• 54. FermaVir Pharmaceuticals, Inc. (USA) IV-171
• 55. Flamel Technologies SA (France) IV-172
• Table 196: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-173
• Table 197: Annual Sales Analysis: 2004-2005 (In US$ million) IV-173
• Table 198: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-173
• Table 199: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-173
• 56. Forest Laboratories, Inc. (USA) IV-176
• Table 200: First Quarter Sales Analysis: 2006-2007 (In US$ billion) IV-177
• Table 201: Annual Sales Analysis: 2004-2006 (In US$ billion) IV-177
• Table 202: Annual Sales Analysis by Quarter: 2005-2006 (In US$ billion) IV-177
• Table 203: Annual Sales Analysis by Product: 2005-2006 (In US$ billion) IV-178
• Table 204: Annual Sales Analysis by Geographic Region: 2005-2006 (In US$ billion) IV-178
• 57. Galapagos NV (Belgium) IV-182
• 58. Genentech, Inc. (USA) IV-184
• Table 205: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-186
• Table 206: Annual Sales Analysis: 2004-2005 (In US$ million) IV-186
• Table 207: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-186
• 59. Gen-Probe, Inc. (USA) IV-191
• Table 208: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-192
• Table 209: Annual Sales Analysis: 2004-2005 (In US$ million) IV-192
• Table 210: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-192
• 60. Gilead Sciences, Inc. (USA) IV-197
• Table 211: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In USS$ million) IV-198
• Table 212: Half Yearly Sales Analysis by Geographic Region: 2005-2006 (H1) (In USS$ million) IV-198
• Table 213: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-198
• Table 214: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-199
• 61. Girindus AG (Germany) IV-204
• 62. GlaxoSmithKline PLC (UK) IV-205
• Table 215: Annual Sales Analysis: 2003-2005 (In £ million) IV-206
• Table 216: Annual Sales Analysis by Segment: 2004-2005 (In £ million) IV-206
• Table 217: Annual Sales Analysis by Segment: 2003-2004 (In £ million) IV-206
• 63. Health Enhancement Products, Inc. (USA) IV-214
• 64. Hemispherx Biopharma, Inc. (USA) IV-215
• Table 218: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ thousand) IV-215
• 65. Hetero Drugs Ltd. (India) IV-216
• 66. Human Genome Sciences, Inc. (USA) IV-217
• Table 219: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ million) IV-218
• Table 220: Annual Sales Analysis: 2003-2005 (In US$ million) IV-218
• 67. Idenix Pharmaceuticals, Inc. (USA) IV-225
• Table 221: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-225
• Table 222: Annual Sales Analysis: 2004-2005 (In US$ million) IV-226
• Table 223: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-226
• 68. Idera Pharmaceuticals, Inc. (USA) IV-227
• 69. Indian Immunologicals Ltd. (India) IV-228
• 70. Innogenetics NV (Belgium) IV-231
• Table 224: Half Yearly Sales Analysis: 2004-2005 (H1) (In € million) IV-232
• Table 225: Half Yearly Sales Analysis by Segment: 2004-2005 (H1) (In € million) IV-232
• 71. Inovio Biomedical Corporation (USA) IV-240
• Table 226: Half Yearly Sales Analysis by: 2005-2006 (H1) (In US$ million) IV-240
• Table 227: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million) IV-241
• Table 228: Annual Sales Analysis: 2003-2005 (In US$ million) IV-241
• Table 229: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-241
• 72. Intarcia Therapeutics Inc. (USA) IV-245
• 73. Intercell AG (Austria) IV-246
• Table 230: Half Yearly Sales Analysis: 2005-2006 (H1) (In € thousand) IV-246
• Table 231: Annual Sales Analysis: 2004-2005 (In € thousand) IV-246
• 74. InterMune, Inc. (USA) IV-248
• Table 232: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-248
• Table 233: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ million) IV-248
• Table 234: Half Yearly Sales Analysis by Geographic Region: 2005-2006 (H1) (In US$ million) IV-249
• Table 235: Annual Sales Analysis: 2003-2005 (In US$ million) IV-249
• Table 236: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-249
• Table 237: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-249
• 75. Isis Pharmaceuticals, Inc. (USA) IV-251
• Table 238: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-251
• Table 239: First Quarter Sales Analysis by Segment: 2005-2006 (In US$ million) IV-252
• Table 240: Annual Sales Analysis: 2004-2005 (In US$ million) IV-252
• Table 241: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-252
• Table 242: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-252
• 76. Japan Tobacco, Inc. (Japan) IV-255
• Table 243: Annual Sales Analysis: 2004-2006 (In ¥ billion) IV-257
• Table 244: Annual Sales Analysis by Segment: 2005-2006 (In ¥ billion) IV-257
• Table 245: Annual Sales Analysis by Geographic Region: 2005-2006 (In ¥ billion) IV-257
• Table 246: Annual Sales Analysis by Segment: 2004-2005 (In ¥ billion) IV-258
• Table 247: Annual Sales Analysis by Geographic Region: 2004-2005 (In ¥ billion) IV-258
• 77. Johnson & Johnson (USA) IV-260
• Table 248: First Quarter Sales Analysis: 2005-2006 (In US$ billion) IV-261
• Table 249: First Quarter Sales Analysis by Segment: 2005-2006 (In US$ billion) IV-261
• Table 250: First Quarter Sales Analysis by Geographic Region: 2005-2006 (Q1) (In US$ billion) IV-261
• Janssen LP (USA) IV-266
• Ortho-Clinical Diagnostics (USA) IV-267
• Ortho Biotech Products - Tibotec Therapeutics Division (USA) IV-269
• Tibotec Pharmaceuticals Ltd. (Ireland) IV-269
• 78. Koronis Pharmaceuticals, Inc. (USA) IV-270
• 79. Lupin Limited (India) IV-271
• Table 251: First Quarter Sales Analysis: 2006-2007 (In INR billion) IV-271
• Table 252: Annual Sales Analysis: 2004-2006 (In INR billion) IV-272
• 80. Medigene AG (Germany) IV-277
• Table 253: Half Yearly Sales Analysis: 2005-2006 (H1) (In € million) IV-277
• Table 254: Half Yearly Sales Analysis by Quarter: 2005-2006 (In € million) IV-277
• Table 255: Annual Sales Analysis: 2004-2005 (In € million) IV-278
• 81. Medimmune, Inc. (USA) IV-280
• Table 256: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-281
• Table 257: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million) IV-281
• Table 258: Annual Sales Analysis: 2004-2005 (In US$ million) IV-282
• Table 259: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-282
• 82. Medivir AB (Sweden) IV-285
• Table 260: Annual Sales Analysis: 2004-2005 (In SEK million) IV-285
• 83. Merck & Company, Inc. (USA) IV-287
• Table 261: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-288
• Table 262: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million) IV-288
• Table 263: Half Yearly Sales Analysis by Product: 2005-2006 (H1) (In US$ million) IV-288
• Table 264: Annual Sales Analysis: 2004-2005 (In US$ million) IV-289
• Table 265: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-289
• Table 266: Annual Sales Analysis by Product: 2004-2005 (In US$ million) IV-289
• Table 267: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-290
• Merck Research Laboratories (USA) IV-293
• 84. MGI Pharma, Inc. (USA) IV-294
• Table 268: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-294
• Table 269: Annual Sales Analysis: 2004-2005 (In US$ million) IV-295
• Table 270: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-295
• 85. Migenix, Inc. (Canada) IV-297
• Table 271: Annual Sales Analysis: 2004-2005 (In US$ million) IV-297
• Table 272: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-298
• 86. Monogram Biosciences, Inc. (USA) IV-300
• Table 273: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-301
• Table 274: Annual Sales Analysis: 2004-2005 (In US$ million) IV-301
• Table 275: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-301
• 87. Novactyl, Inc. (USA) IV-302
• 88. Novartis AG (Switzerland) IV-303
• Table 276: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-306
• Table 277: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ million) IV-307
• Table 278: Annual Sales Analysis: 2004-2005 (In US$ million) IV-307
• Table 279: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-307
• Table 280: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-307
• Chiron Corporation (USA) IV-316
• Novartis Pharmaceuticals Corporation (USA) IV-322
• Sandoz International GmbH (Germany) IV-326
• 89. Novelos Therapeutics (USA) IV-328
• Table 281: Annual Sales Analysis: 2004-2005 (In US$ million) IV-329
• 90. Novosom AG (Germany) IV-330
• 91. Nucleonics, Inc. (USA) IV-330
• 92. Oncogene Science, Inc. (USA) IV-331
• 93. OraSure Technologies, Inc. (USA) IV-333
• Table 282: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-334
• Table 283: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million) IV-334
• Table 284: Half Yearly Sales Analysis by Segment: 2005-2006 (In US$ million) IV-334
• Table 285: Half Yearly Sales Analysis by Geographic Region: 2005-2006 (H1) (In US$ million) IV-335
• Table 286: Annual Sales Analysis: 2003-2005 (In US$ million) IV-335
• Table 287: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-335
• Table 288: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-335
• Table 289: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-335
• 94. Oxford BioMedica PLC (UK) IV-340
• Table 290: Annual Sales Analysis: 2004-2005 (In £ million) IV-340
• 95. Panacos Pharmaceuticals, Inc. (USA) IV-344
• 96. Pasteur Merieux Connaught (France) IV-345
• 97. PDL BioPharma, Inc. (USA) IV-346
• Table 291: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-347
• Table 292: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million) IV-348
• Table 293: Annual Sales Analysis: 2003-2005 (In US$ million) IV-348
• 98. Peregrine Pharmaceuticals, Inc. (USA) IV-351
• Table 294: Annual Sales Analysis: 2004-2006 (In US$ million) IV-351
• Table 295: Annual Sales Analysis by Quarter: 2005-2006 (In US$ million) IV-352
• Table 296: Annual Sales Analysis by Segment: 2005-2006 (In US$ million) IV-352
• Table 297: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-352
• 99. Pfizer, Inc. (USA) IV-354
• Table 298: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ billion) IV-356
• Table 299: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ billion) IV-356
• Table 300: Half Yearly Sales Analysis by Geographic Region: 2005-2006 (H1) (In US$ billion) IV-357
• Table 301: Annual Sales Analysis: 2004-2005 (In US$ billion) IV-357
• 100. Pharmasset, Inc. (USA) IV-361
• 101. Pharmexa A/S (Denmark) IV-362
• Table 302: Half Yearly Sales Analysis: 2005-2006 (H1) (In DKK million) IV-362
• 102. Procter & Gamble Pharmaceuticals (USA) IV-366
• 103. Receptopharm, Inc. (USA) IV-368
• 104. REPLICor, Inc. (Canada) IV-369
• 105. Rhein Biotech NV (The Netherlands) IV-370
• 106. Sanofi-Aventis (France) IV-371
• Table 303: Half Yearly Sales Analysis: 2005-2006 (H1) (In € million) IV-372
• Table 304: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In € million) IV-372
• Table 305: Annual Sales Analysis: 2004-2005 (In € million) IV-372
• Table 306: Annual Sales Analysis by Segment: 2004-2005 (In € million) IV-372
• Table 307: Annual Sales Analysis by Geographic Region: 2004-2005 (In € million) IV-373
• 107. Sareum Ltd. (UK) IV-378
• 108. Schering AG (Germany) IV-380
• Table 308: First Quarter Sales Analysis: 2005-2006 (In € billion) IV-381
• Table 309: First Quarter Sales Analysis by Segment: 2005-2006 (In € billion) IV-381
• Table 310: First Quarter Sales Analysis by Geographic Region: 2005-2006 (In € billion) IV-382
• Table 311: Annual Sales Analysis: 2004-2005 (In € billion) IV-382
• Table 312: Annual Sales Analysis by Segment: 2004-2005 (In € billion) IV-382
• Table 313: Annual Sales Analysis by Geographic Region: 2004-2005 (In € billion) IV-382
• Schering-Plough Corporation (USA) IV-387
• 109. SciClone Pharmaceuticals, Inc. (USA) IV-391
• Table 314: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-391
• Table 315: Annual Sales Analysis: 2004-2005 (In US$ million) IV-392
• 110. Scigen Ltd. (Australia) IV-393
• Table 316: Annual Sales Analysis: 2005-2006 (In S$ thousand) IV-393
• Table 317: Annual Sales Analysis by Geographic Region: 2005-2006 (In S$ thousand) IV-393
• 111. Serum Institute of India Ltd. (India) IV-396
• 112. SGX Pharmaceuticals, Inc.(USA) IV-398
• Table 318: First Quarterly Sales Analysis: 2005-2006 (In US$ million) IV-398
• Table 319: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-399
• Table 320: Annual Sales Analysis: 2004-2005 (In US$ million) IV-399
• 113. Shantha Biotechnics Pvt., Ltd. (India) IV-401
• 114. Shionogi & Co., Ltd. (Japan) IV-403
• Table 321: Annual Sales Analysis: 2004-2005 (In ¥ million) IV-403
• Table 322: Annual Sales Analysis by Segment: 2004-2005 (In ¥ million) IV-404
• 115. Sunesis Pharmaceuticals, Inc. (USA) IV-406
• Table 323: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-406
• Table 324: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million) IV-407
• Table 325: Annual Sales Analysis: 2004-2005 (In US$ million) IV-407
• Table 326: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-407
• 116. Takeda Pharmaceutical Company Limited (Japan) IV-409
• Table 327: Annual Sales Analysis: 2004-2006 (In ¥ billion) IV-410
• 117. Targeted Genetics Corporation (USA) IV-414
• Table 328: Half Yearly Sales Analysis: 2005-2006 (In US$ million) IV-414
• Table 329: Annual Sales Analysis: 2003-2005 (In US$ million) IV-415
• 118. TEVA Pharmaceutical Industries Ltd. (Israel) IV-417
• Table 330: Half Yearly Sales Analysis: 2004-2005 (H1) (In US$ billion) IV-417
• Table 331: Half Yearly Sales Analysis by Segment: 2004-2005 (H1) (In US$ billion) IV-418
• Table 332: Half Yearly Geographic Sales Analysis: 2004-2005 (H1) (In US$ billion) IV-418
• Ivax Corporation (USA) IV-422
• 119. The Immune Response Corporation (USA) IV-428
• Table 333: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ thousand) IV-429
• Table 334: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ thousand) IV-429
• Table 335: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ thousand) IV-429
• Table 336: Annual Sales Analysis: 2003-2005 (In US$ thousand) IV-429
• Table 337: Annual Sales Analysis by Quarter: 2004-2005 (In US$ thousand) IV-429
• Table 338: Annual Sales Analysis by Segment: 2004-2005 (In US$ thousand) IV-430
• 120. Three Rivers Pharmaceuticals (USA) IV-433
• 121. Titan Pharmaceuticals, Inc. (USA) IV-435
• 122. Trimeris, Inc. (USA) IV-436
• Table 339: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-436
• 123. Trinity Biotech PLC (Ireland) IV-439
• Table 340: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-440
• Table 341: First Quarter Sales Analysis by Product: 2005-2006 (In US$ million) IV-440
• Table 342: First Quarter Sales Analysis by Geographic Region: 2005-2006 (In US$ million) IV-440
• Table 343: Annual Sales Analysis: 2004-2005 (In US$ million) IV-441
• Table 344: Annual Sales Analysis by Product: 2004-2005 (In US$ million) IV-441
• Table 345: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-441
• 124. Tripep AB (Sweden) IV-444
• 125. Valeant Pharmaceuticals International (USA) IV-445
• Table 346: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-446
• Table 347: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million) IV-446
• Table 348: Annual Sales Analysis: 2004-2005 (In US$ million) IV-446
• Table 349: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-446
• 126. VaxGen, Inc. (USA) IV-450
• 127. Vertex Pharmaceuticals, Inc. (USA) IV-453
• Table 350: First Quarter Sales Analysis: 2006-2005 (In US$ million) IV-454
• Table 351: Annual Sales Analysis: 2003-2005 (In US$ million) IV-454
• Table 352: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-454
• 128. Vical, Inc. (USA) IV-456
• Table 353: Half Yearly Sales Analysis: 2005-2006 (In US$ million) IV-457
• Table 354: Half Yearly Sales Analysis by Quarter: 2005-2006 (In US$ million) IV-457
• Table 355: Annual Sales Analysis: 2004-2005 (In US$ million) IV-457
• Table 356: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-457
• 129. Vion Pharmaceuticals (USA) IV-460
• 130. Viragen, Inc. (USA) IV-461
• Table 357: Annual Sales Analysis: 2004-2006 (In US$ million) IV-462
• Table 358: Annual Sales Analysis by Geographic Region: 2005-2006 (In US$ million) IV-462
• Table 359: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-462
• 131. Virco Laboratories, Inc. (USA) IV-464
• 132. ViroPharma, Inc. (USA) IV-465
• Table 360: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-465
• Table 361: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million) IV-466
• Table 362: Annual Sales Analysis: 2004-2005 (In US$ million) IV-466
• 133. Viscount Pharma, Inc. (Canada) IV-467
• 134. Vybion, Inc. (USA) IV-468
• 135. Wyeth (USA) IV-469
• Table 363: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ billion) IV-471
• Table 364: Half Yearly Sales Analysis by Segment: 2006-2005 (H1) (In US$ billion) IV-471
• Table 365: Annual Sales Analysis: 2004-2005 (In US$ billion) IV-471
• Table 366: Annual Sales Analysis by Segment: 2004-2005 (In US$ billion) IV-471
• Table 367: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ billion) IV-471
• 136. Xenomics, Inc. (USA) IV-476
• 137. XTL Biopharmaceuticals Ltd. (USA) IV-477
• Table 368: Annual Sales Analysis: 2004-2005 (In US$ million) IV-477
• 138. ZymeTx, Inc. (USA) IV-478
• 139. ZymoGenetics, Inc. (USA) IV-480
• Table 369: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-480
• Table 370: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million) IV-481
• Table 371: Annual Sales Analysis: 2004-2005 (In US$ million) IV-481